Stockreport

Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

Arcus Biosciences, Inc.  (RCUS) 
Last arcus biosciences, inc. earnings: 3/5 04:10 pm Check Earnings Report
PDF The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expan [Read more]